Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii.
Nosocomial bacteremia caused by extensively resistant Acinetobacter baumannii (ERAB) is an emerging problem in Taiwanese hospitals. Accordingly, we retrospectively investigated the epidemiology and outcomes of adult patients with ERAB bacteremia (ERABB) after different treatments from January 2001 to September 2004 at the National Taiwan University Hospital, Taipei, Taiwan. A total of 56 adult patients with ERABB and without other simultaneous infections were enrolled. Demographic, clinical, and laboratory data were obtained from medical records. Clinical data included underlying diseases and conditions with onset within 7 days after ERABB, severity of ERABB, antibiotic regimens for ERABB, and clinical outcomes. Laboratory data included hemograms, liver function tests, renal function tests, and albumin levels. Coagulation profiles were obtained at ERABB onset and 7 days before and after onset. All 56 episodes of ERABB were hospital-acquired. Most patients had Acute Physiology Scores and Chronic Health Evaluation II scores >/=17 (66.1%) and Pitt bacteremia score >/=4 (66.1%). Many had comorbid diseases at ERABB onset. Crude mortality rates on days 2, 7, 15, 30, and at discharge were 23.2%, 30.4%, 37.5%, 48.2%, and 60.7%, respectively. High severity of ERABB (Pitt bacteremia score >/=4) and presence of immunosuppression were the only 2 predictors for day 30 mortality (odds ratios of 18.53 and 8.06, respectively). Antibiotic regimens for ERABB did not have a significant influence on ERABB outcomes.
Tseng
Yu-Chen
YC
Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Wang
Jann-Tay
JT
Wu
Fe-Lin Lin
FL
Chen
Yee-Chun
YC
Chie
Wei-Chu
WC
Chang
Shan-Chwen
SC
D000151:Acinetobacter Infections / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000472:pathogenicity; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D013624:Taiwan
D000900:Anti-Bacterial Agents